Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Metagenomi Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Metagenomi Therapeutics, Inc.’s stock price such as:

• Metagenomi Therapeutics, Inc.’s current stock price and volume
• Why Metagenomi Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for MGX from analysts
• MGX’s stock price momentum as measured by its relative strength

About Metagenomi Therapeutics, Inc. (MGX)

Before we jump into Metagenomi Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company’s lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.

Want to learn more about Metagenomi Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Metagenomi Therapeutics, Inc..

Metagenomi Therapeutics, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Metagenomi Therapeutics, Inc.’s stock price was $1.190.

Metagenomi Therapeutics, Inc. is down 2.46% from its previous closing price of $1.220.

During the last market session, Metagenomi Therapeutics, Inc.’s stock traded between $1.185 and $1.220. Currently, there are approximately 37.58 million shares outstanding for Metagenomi Therapeutics, Inc..

Metagenomi Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Metagenomi Therapeutics, Inc. Stock Price History

During the month of July, Metagenomi Therapeutics, Inc.’s stock price has not significantly increased or decreased. In order to understand the stock price forecast for Metagenomi Therapeutics, Inc., you may need to analyze their annual trend or other metrics instead.

Over the last year, Metagenomi Therapeutics, Inc. has hit prices as high as $3.950 and as low as $1.130. Year to date, Metagenomi Therapeutics, Inc.’s stock is down 26.54%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Metagenomi Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were 0 analysts who downgraded Metagenomi Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Metagenomi Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Metagenomi Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Metagenomi Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a A, which means it is considered to be Deep Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Metagenomi Therapeutics, Inc. (MGX) by visiting AAII Stock Evaluator.

Relative Price Strength of Metagenomi Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Metagenomi Therapeutics, Inc. has a weighted four-quarter relative price strength of -17.80%, which translates to a Momentum Score of 14 and is considered to be Very Weak.

Want to learn more about how Metagenomi Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Metagenomi Therapeutics, Inc. Stock Price: Bottom Line

As of July 31, 2026, Metagenomi Therapeutics, Inc.’s stock price is $1.190, which is down 2.46% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Metagenomi Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.